John Libbey Eurotext

Hématologie

MENU

Mechanisms of resistance to targeted therapies Ahead of print

Figures

  • Figure 1
Author
Service d’hématologie clinique et de thérapie cellulaire, CHU de Clermont-Ferrand
Équipe Chelter, Université Clermont Auvergne
* Correspondence

The therapeutic landscape for patients with chronic lymphocytic leukaemia is growing with the advent of BCR inhibitors and the BCL2 inhibitor, venetoclax. Cases of resistance are emerging, and the underlying mechanisms, such as mutations affecting the therapeutic target, are highlighted and presented in this review.